MicroRNA Networks in Cognition and Dementia.
Cells
; 11(12)2022 06 09.
Article
in English
| MEDLINE | ID: covidwho-1884016
ABSTRACT
The change from viewing noncoding RNA as "junk" in the genome to seeing it as a critical epigenetic regulator in almost every human condition or disease has forced a paradigm shift in biomedical and clinical research. Small and long noncoding RNA transcripts are now routinely evaluated as putative diagnostic or therapeutic agents. A prominent role for noncoding microRNAs in the central nervous system has uncovered promising new clinical candidates for dementia-related disorders, treatments for which currently remain elusive even as the percentage of diagnosed patients increases significantly. Cognitive decline is a core neurodegenerative process in Alzheimer's Disease, Frontotemporal Dementia, Lewy body dementia, vascular dementia, Huntington's Disease, Creutzfeldt-Jakob disease, and a significant portion of Parkinson's Disease patients. This review will discuss the microRNA-associated networks which influence these pathologies, including inflammatory and viral-mediated pathways (such as the novel SARS-CoV-2 virus implicated in COVID-19), and their current status in clinical trials.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cognition
/
Dementia
/
MicroRNAs
Type of study:
Experimental Studies
/
Prognostic study
Limits:
Humans
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
Cells11121882
Similar
MEDLINE
...
LILACS
LIS